10-K: RetinalGenix Technologies Inc. Files 10-K, Outlines Progress in Ophthalmic and Systemic Disease Solutions

RetinalGenix Technologies Inc. has filed its annual 10-K report, detailing its progress in developing medical devices and therapeutic candidates for ophthalmic and systemic diseases, while also highlighting its financial position and future capital needs.

Summary

• RetinalGenix Technologies Inc. is focused on creating solutions for screening, monitoring, diagnosing, and treating ophthalmic and systemic diseases.
• The company is developing two main devices: a portable retinal imaging system and RetinalCamTM, a home-based monitoring device.
• RetinalGenix is also developing drug candidates RTG-2023 for dry age-related macular degeneration and RTG-2024 for Alzheimer's syndrome dementia.
• The company has not generated any revenue from product sales and has funded operations primarily through private placements of common stock.
• RetinalGenix anticipates needing an additional $12.2 million to complete product development, expand software tools, and build infrastructure.
• The company plans to obtain funds through equity and debt sales, and potential strategic partnerships.
• The company acquired DNA/GPS Inc. in July 2022, combining pharmacogenetic mapping with retinal imaging capabilities.
• RetinalGenix expects to launch RetinalCamTM by the end of Q3 2024 and is seeking FDA clearance for RetinalGeniXTM in 2024.
• The company has engaged Avania Clinical as an advisor for therapeutic drug development and has filed two provisional patents related to its studies.
• The company has ended its relationship with MEDsan due to facility damage and has replaced it with Seven Springs Surgery Center for blood draws.
• The company has a sublicense agreement with Sanovas Ophthalmology for certain intellectual property related to eye visualization and monitoring.

Sentiment

Score: 4

Explanation: The document highlights significant progress in product development and strategic partnerships, but the lack of revenue, substantial losses, and going concern issues temper the overall sentiment. The need for significant additional funding and the presence of material weaknesses in internal controls also contribute to a cautious outlook.

Positives

• The company is actively developing innovative medical devices and therapeutic candidates.
• The acquisition of DNA/GPS Inc. enhances the company's diagnostic capabilities.
• The company has a clear timeline for the launch of RetinalCamTM by the end of Q3 2024.
• The company has engaged a leading optical design firm to accelerate its development timeline.
• The company has expanded its Therapeutics Advisory Committee with experienced professionals.
• The company has filed provisional patents for two drug candidates.

Negatives

• The company has not generated any revenue from product sales.
• The company has incurred net losses every year and expects to continue to incur increased expenses.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on third-party suppliers for components.
• The company faces substantial competition in the medical device and drug development markets.
• The company's management overlaps substantially with the management of its principal stockholder, which may lead to conflicts of interest.
• The company has a material weakness in its internal controls over financial reporting due to a lack of segregation of duties.

Risks

• The company's future profitability is uncertain, and it may not be able to achieve or maintain profitability.
• Failure to obtain necessary capital could halt product development and result in loss of investment.
• Raising additional capital may dilute existing stockholders' ownership.
• The company's products may not be accepted in the market, and it may face substantial competition.
• Product liability lawsuits could cause substantial liabilities.
• Failure to comply with data privacy and security laws could have a material adverse effect.
• The company may not be successful in hiring and retaining key employees.
• The company's intellectual property may not be sufficient to protect its products from competition.
• Failure to obtain and maintain FDA clearances or approvals would prevent commercialization in the U.S.
• The company's stock price may be volatile, and future sales of securities could result in additional dilution.
• The company is subject to the penny stock rules of the SEC, making transactions in its stock cumbersome.
• Certain stockholders control a significant number of shares, which may affect corporate control.
• The company has availed itself of reduced disclosure requirements applicable to emerging growth companies, which could make its stock less attractive to investors.
• The company's Certificate of Incorporation and Bylaws may have anti-takeover effects that could discourage a change in control.
• The company's financial reporting obligations are expensive and time-consuming.
• Halo Management LLC may contest the rescission of 3,000,000 shares of Series F Preferred Stock.

Future Outlook

The company expects to continue to incur losses and will need substantial additional funding to support its operations and growth strategy. The company intends to launch RetinalCamTM by the end of Q3 2024 and is seeking FDA clearance for RetinalGeniXTM in 2024. The company plans to obtain funds through equity and debt sales, and potential strategic partnerships.

Management Comments

• Management believes that the company will need to raise substantial additional capital to fund its continuing operations and the development and commercialization of its products.
• Management intends to obtain such funds through the sales of our equity and debt securities and/or through potential strategic partnerships.
• Management is working to remediate the material weakness in internal controls, but there is no assurance that such changes will prevent or detect future material weaknesses.

Industry Context

The company operates in the competitive ophthalmic medical technology and pharmaceutical industries, facing competition from larger organizations with more resources. The company's focus on early detection and home-based monitoring aligns with trends in healthcare towards preventative and remote care.

Comparison to Industry Standards

• RetinalGenix is an early-stage company compared to established players in the ophthalmic medical technology industry, such as Alcon, Johnson & Johnson Vision, and Bausch + Lomb, which have significantly greater financial resources and established distribution networks.
• The company's focus on combining retinal imaging with pharmacogenetic mapping is a unique approach compared to traditional diagnostic methods, which often rely on separate tests and specialized centers.
• The company's development of home-based monitoring devices like RetinalCamTM aligns with the trend towards remote patient monitoring, which is being adopted by companies like Livongo and Teladoc in other healthcare sectors.
• The company's drug development efforts for dry AMD and Alzheimer's are in a highly competitive space, with companies like Apellis Pharmaceuticals and Biogen already having approved treatments or advanced clinical programs.
• The company's reliance on third-party suppliers for components is common in the medical device industry, but it exposes them to supply chain risks, similar to other companies in the sector.

Management Changes

Legal Proceedings

• Sanovas, Inc. commenced an action in the Court of Chancery of the State of Delaware against Halo Management LLC and Lawrence Gerrans seeking an order declaring that any rights that Halo and/or Mr. Gerrans may have with respect to any equity securities in Sanovas and each of its affiliated subsidiaries (including, but not limited to, our Company) are void or voidable and may be cancelled.
• The company's board of directors resolved to rescind the 3,000,000 shares of Series F Preferred Stock purported issued to Halo for lack of contract consideration.

Related Party Transactions

• The company has a sublicense agreement with Sanovas Ophthalmology for certain intellectual property.
• Sanovas has paid a significant portion of the company's operating expenses and allocated costs to the company.
• The company has settled a portion of the amounts due to Sanovas through the periodic issuance of shares of common stock.
• The company has received advances from related parties, including an officer of the company, a shareholder of the company and affiliates of Sanovas.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional capital.
• Employees and consultants may be affected by the company's financial instability and potential delays in product development.
• Customers and patients may experience delays in the availability of the company's products due to regulatory hurdles and financial constraints.
• Suppliers and creditors may face uncertainty regarding payment due to the company's financial position.

Next Steps

• Complete product design and testing for RetinalGeniXTM and RetinalCamTM.
• Submit RetinalGeniXTM for FDA clearance.
• Complete the development and expansion of the software tools around the DNA/GPS genetic mapping technology.
• Build the infrastructure for sustained growth.
• Launch RetinalCamTM by the end of Q3 2024.
• Conduct clinical studies of TRG 2023 and RTG 2024 products.

Key Dates

Keywords

Ophthalmic, Retinal Imaging, Medical Devices, Therapeutics, Macular Degeneration, Alzheimer's, Pharmacogenetics, FDA Clearance, Drug Development, Biomarkers, DNA/RNA, Clinical Trials